These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 24992038)

  • 21. Unique immunogenicity of hepatitis B virus DNA vaccine presented by live-attenuated Salmonella typhimurium.
    Woo PC; Wong LP; Zheng BJ; Yuen KY
    Vaccine; 2001 Apr; 19(20-22):2945-54. PubMed ID: 11282206
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vaccination with a DNA vaccine encoding CD317-targeting HBs antigen elicits enhanced immunity in mice.
    Zhang G; Li X; Liu L; Li J; Chen Q; Huang S; Li Y; Wan X
    Biochem Biophys Res Commun; 2018 Oct; 504(4):865-870. PubMed ID: 30219230
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Breaking B and T cell tolerance using cationic lipid--DNA complexes (CLDC) as a vaccine adjuvant with hepatitis B virus (HBV) surface antigen in transgenic mice expressing HBV.
    Morrey JD; Motter NE; Chang S; Fairman J
    Antiviral Res; 2011 Jun; 90(3):227-30. PubMed ID: 21545812
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Engineering enhancement of the immune response to HBV DNA vaccine in mice by the use of LIGHT gene adjuvant.
    Zhang Y; Jiang W; Fan Y; Wen J; Hao W; Qian M
    J Virol Methods; 2008 Nov; 153(2):142-8. PubMed ID: 18722475
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HBV antigen and DNA loss from mouse serum is associated with novel vaccine-induced HBV surface antigen-specific cell-mediated immunity and cytokine production.
    Chuai X; Xie B; Deng Y; Zhao Y; Wang W; Gao Z; Wang W; Qiu X; Tan W
    Antiviral Res; 2019 Jan; 161():20-27. PubMed ID: 30423362
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cloning, protein expression and immunogenicity of HBs-murine IL-18 fusion DNA vaccine.
    Channarong S; Mitrevej A; Sinchaipanid N; Usuwantim K; Kulkeaw K; Chaicumpa W
    Asian Pac J Allergy Immunol; 2007 Dec; 25(4):233-42. PubMed ID: 18402297
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Enhanced immunogenicity of DNA fusion vaccine encoding secreted hepatitis B surface antigen and chemokine RANTES.
    Kim SJ; Suh D; Park SE; Park JS; Byun HM; Lee C; Lee SY; Kim I; Oh YK
    Virology; 2003 Sep; 314(1):84-91. PubMed ID: 14517062
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of the HCV core protein on the immune response to HBV surface antigen and on HBV gene expression and replication in vivo.
    Zhu W; Wu C; Deng W; Pei R; Wang Y; Cao L; Qin B; Lu M; Chen X
    PLoS One; 2012; 7(9):e45146. PubMed ID: 23024803
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oral administration of synthetic selenium nanoparticles induced robust Th1 cytokine pattern after HBs antigen vaccination in mouse model.
    Mahdavi M; Mavandadnejad F; Yazdi MH; Faghfuri E; Hashemi H; Homayouni-Oreh S; Farhoudi R; Shahverdi AR
    J Infect Public Health; 2017; 10(1):102-109. PubMed ID: 27026241
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cationic lipid DC-Chol induces an improved and balanced immunity able to overcome the unresponsiveness to the hepatitis B vaccine.
    Brunel F; Darbouret A; Ronco J
    Vaccine; 1999 Apr; 17(17):2192-203. PubMed ID: 10367954
    [TBL] [Abstract][Full Text] [Related]  

  • 31. TH1 and TH2 responses are influenced by HLA antigens in healthy neonates vaccinated with recombinant hepatitis B vaccine.
    Jafarzadeh A; Shokri F
    Iran J Allergy Asthma Immunol; 2012 Dec; 11(4):308-15. PubMed ID: 23264407
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pre-clinical evaluation of a novel nanoemulsion-based hepatitis B mucosal vaccine.
    Makidon PE; Bielinska AU; Nigavekar SS; Janczak KW; Knowlton J; Scott AJ; Mank N; Cao Z; Rathinavelu S; Beer MR; Wilkinson JE; Blanco LP; Landers JJ; Baker JR
    PLoS One; 2008 Aug; 3(8):e2954. PubMed ID: 18698426
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Plasmids enriched with CpG motifs activate human peripheral blood mononuclear cells in vitro and enhance th-1 immune responses to hepatitis B surface antigen in mice.
    Chen Z; Cao J; Liao X; Ke J; Zhu S; Zhao P; Qi Z
    Viral Immunol; 2011 Jun; 24(3):199-209. PubMed ID: 21668361
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Modulation of gene-gun-mediated Th2 immunity to hepatitis B surface antigen by bacterial CpG motifs or IL-12.
    Schirmbeck R; Reimann J
    Intervirology; 2001; 44(2-3):115-23. PubMed ID: 11509872
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Whole recombinant Hansenula polymorpha expressing hepatitis B virus surface antigen (yeast-HBsAg) induces potent HBsAg-specific Th1 and Th2 immune responses.
    Bian G; Cheng Y; Wang Z; Hu Y; Zhang X; Wu M; Chen Z; Shi B; Sun S; Shen Y; Chen EJ; Yao X; Wen Y; Yuan Z
    Vaccine; 2009 Dec; 28(1):187-94. PubMed ID: 19789093
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Induction of a robust T- and B-cell immune response in non- and low-responders to conventional vaccination against hepatitis B by using a third generation PreS/S vaccine.
    Krawczyk A; Ludwig C; Jochum C; Fiedler M; Heinemann FM; Shouval D; Roggendorf M; Roggendorf H; Lindemann M
    Vaccine; 2014 Sep; 32(39):5077-82. PubMed ID: 24975813
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A comparative trial of two surface subunit recombinant hepatitis B vaccines vs a surface and PreS subunit vaccine for immunization of healthy adults.
    Eyigün CP; Yilmaz S; Gül C; Sengül A; Hacibektasoglu A; Van Thiel DH
    J Viral Hepat; 1998 Jul; 5(4):265-9. PubMed ID: 9751013
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recombinant hepatitis B core antigen carrying preS1 epitopes induce immune response against chronic HBV infection.
    Chen X; Li M; Le X; Ma W; Zhou B
    Vaccine; 2004 Jan; 22(3-4):439-46. PubMed ID: 14670326
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Testing of CpG-optimized protein and DNA vaccines against the hepatitis B virus in chimpanzees for immunogenicity and protection from challenge.
    Payette PJ; Ma X; Weeratna RD; McCluskie MJ; Shapiro M; Engle RE; Davis HL; Purcell RH
    Intervirology; 2006; 49(3):144-51. PubMed ID: 16428890
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel immunogenicity of Oka varicella vaccine vector expressing hepatitis B surface antigen.
    Kamiyama T; Sato H; Takahara T; Kageyama S; Shiraki K
    J Infect Dis; 2000 Mar; 181(3):1158-61. PubMed ID: 10720546
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.